Medicine Overview

Indication

Know Medicine, Follow Guideline

Adult Dose

Clinical InformationAdministration Information
Indication: Acute promyelocytic leukaemia
Age: Adult
Dose: Oral – 45 mg/m2
Frequency: daily in 2 divided doses
Duration: Treatment is continued until 30 days after complete remission or up to 90 days, whichever occurs first
Indication: Acute promyelocytic leukaemia
Age: Adult
Condition: Hepatic impairment
Dose: Oral – 25 mg/m2
Frequency: daily
Note: Reduce dose to 25 mg/m2 daily in patients with hepatic impairment

Child Dose

Clinical InformationAdministration Information
Indication: Acute promyelocytic leukaemia
Age: 1-16 yr
Dose: Oral – 45 mg/m2
Frequency: daily in 2 divided doses
Duration: until 30 days after complete remission or up to 90 days, whichever occurs first
Indication: Acute promyelocytic leukaemia
Age: 1-16 yr
Condition: Hepatic impairment
Dose: Oral – 25 mg/m2
Frequency: daily

Renal Dose

Clinical InformationAdministration Information
Condition: Renal impairment
Dose: Not specified – 25 mg/m2
Frequency: daily
Note: Reduce dose to 25 mg/m2 daily for renal impairment
Administration
  • Take with food
  • Take exactly as prescribed
Side Effect

Drug Interaction

Drug NameRisk Factors
Minoxidil
Enhances percutaneous absorption
Antifibrinolytic
Potentially Fatal: Increased risk of fatal thrombotic complications

Disease Interaction

Disease NameRisk Factors
Eczematous Skin
Risk of severe skin irritation
Sunburnt/Abraded Skin
Risk of increased irritation

Pregnancy

Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store at 15° to 30°C. Protect from light.

Data Sources

Clinical & regulatory information on this page is compiled from the following government sources:

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.